Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

How behavioural design is transforming the role and impact of life sciences in healthcare

Behavioural economics will become essential to the future success of life sciences companies

- PMLiVE

Bringing the NHS into the 21st century

As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really...

Blue Latitude Health

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Bluebird Bio: on the cusp of a gene therapy revolution

Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe.

- PMLiVE

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

The Multichannel Masters – the story so far

Since we introduced Vendit and throughout its development into Trustrack, our dedicated Multichannel team have consistently, compliantly and digitally delivered for all our clients at Congresses, events and for their...

Healthcare Media Europe – HME Ltd

- PMLiVE

Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

The next generation of relationship holders will offer highly personalised services

Using contextual moments in marketing

Marketers talk about giving the right message to the right consumer at the right time as a key factor for any campaign. This has become even more refined and targeted...

Page & Page Health

- PMLiVE

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab’s OX40 candidate

The latest from pharma, biotech and healthcare

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

Translating data to create a meaningful story

Embracing data to create numerous possibilities

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links